Babic, Ana http://orcid.org/0000-0003-1199-5958
Rosenthal, Michael H. http://orcid.org/0000-0002-5085-3904
Sundaresan, Tilak K.
Khalaf, Natalia
Lee, Valerie
Brais, Lauren K.
Loftus, Maureen
Caplan, Leah http://orcid.org/0000-0002-6594-1608
Denning, Sarah
Gurung, Anamol
Harrod, Joanna
Schawkat, Khoschy
Yuan, Chen
Wang, Qiao-Li
Lee, Alice A.
Biller, Leah H.
Yurgelun, Matthew B. http://orcid.org/0000-0002-6184-9273
Ng, Kimmie http://orcid.org/0000-0003-0631-1494
Nowak, Jonathan A.
Aguirre, Andrew J. http://orcid.org/0000-0002-0701-6203
Bhatia, Sangeeta N. http://orcid.org/0000-0002-1293-2097
Vander Heiden, Matthew G. http://orcid.org/0000-0002-6702-4192
Van Den Eeden, Stephen K. http://orcid.org/0000-0002-5599-8387
Caan, Bette J.
Wolpin, Brian M. http://orcid.org/0000-0002-0455-1032
Funding for this research was provided by:
Lustgarten Foundation
Pancreatic Cancer Action Network
EIF | Stand Up To Cancer (SU2C-AACR-DT25-17)
Article History
Received: 21 November 2022
Accepted: 4 July 2023
First Online: 18 July 2023
Competing interests
: M.G.V.H. is a scientific advisor for Agios Pharmaceuticals, iTeos Therapeutics, Sage Therapeutics, Faeth Therapeutics, Droia Ventures, and Auron Therapeutics on topics unrelated to the presented work. B.M.W. received research funding from Celgene, Eli Lilly, Novartis, and Revolution Medicine and consulting fees from Celgene, Grail, Mirati, and Third Rock Ventures unrelated to the presented work. M.B.Y. received research grant from Janssen Pharmaceuticals and fees for peer review services from UpToDate, unrelated to the presented work. The remaining authors declare no competing interests.